Published in Cardiovascular Week, January 30th, 2006
Under the agreement, Corautus will provide its proprietary vascular endothelial growth factor, VEGF-2, to CSEMC for evaluation in a 64-patient, phase I trial for the treatment of CLI. CSEMC is the sponsor of this clinical trial which will be conducted under a funding grant from the U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.